MG
ALNY icon

Mather Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mather Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88K Buy
26
+15
+136% +$4.52K ﹤0.01% 1542
2026
Q1 		$3.7K Buy
+11
New +$3.74K ﹤0.01% 1622
2025
Q4 		– Sell
-14
Closed -$6.55K – 679
2025
Q3 		$6.55K Buy
+14
New +$5.7K ﹤0.01% 1341
2025
Q2 		– Sell
-20
Closed -$5.42K – 649
2025
Q1 		$5.42K Buy
20
+8
+67% +$2.06K ﹤0.01% 1391
2024
Q4 		$2.82K Buy
12
+6
+100% +$1.58K ﹤0.01% 1479
2024
Q3 		$1.54K Sell
6
-4
-40% -$1.04K ﹤0.01% 1518
2024
Q2 		$1.49K Buy
10
+3
+43% +$474 ﹤0.01% 1955
2024
Q1 		$1.34K Buy
+7
New +$1.17K ﹤0.01% 1594

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mather Group's ALNY Position: Q2 2026 in Review

Mather Group increased its Alnylam Pharmaceuticals (ALNY) stake by 136% in Q2 2026, buying an estimated $4.52K and bringing the position to 26 shares worth $7.88K. The position accounts for ﹤0.01% of the portfolio, ranked #1542.

Mather Group first reported a position in ALNY in Q1 2024 and has held it in 8 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mather Group held 26 shares of Alnylam Pharmaceuticals worth $7.88K as of Q2 2026.
  • Mather Group bought 15 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.52K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1542 holding.
  • Mather Group first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.